- Home
- Clinical Trials
Chronic Kidney Disease Study Kapiti 13
Chronic Kidney Disease Study
Kapiti
Are you living with chronic kidney disease (CKD)?
We are conducting a clinical research study to evaluate a new potential approach for treating CKD that aims to improve kidney function and delay disease progression.
Join our research study and help find a potential improved treatment strategy for people living with chronic kidney disease.
Description
What to expect
Study details
Ages
18 years or older
Duration
Approximately 12 weeks with 6 scheduled visits to the clinic
Compensation
You will be well compensated for any study related costs
Eligibility Criteria
You may qualify for this study if you:
- Are 18 years or older
- Have chronic kidney disease (CKD) at risk of progression
- Have been on a stable dose of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 4 weeks
- Have not taken an SGLT2 inhibitor in the last 4 weeks
Other criteria will apply.
Locations
Description
Living with Chronic Kidney Disease (CKD) is more than just managing a medical condition—it’s a journey that can affect nearly every aspect of life, from physical health to emotional well-being and daily routines. For many, CKD brings challenges that are not always visible to others but are deeply felt every day.
CKD is a condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood. This can lead to serious health problems, including heart disease and kidney failure.
Although current therapies are beneficial, they do not always prevent the progression of kidney disease, and they cannot address all the complications CKD presents.
This clinical research study aims to slow the progression of CKD, improve quality of life, and reduce the need for invasive treatments like dialysis.
What to expect
We are conducting a clinical research study to evaluate whether starting two currently available medications—vicadrostat and empagliflozin—at the same time is as safe and effective as introducing them one at a time. These medications help protect the kidneys and manage blood pressure in people with Chronic Kidney Disease (CKD). It is hoped that this new approach could improve kidney function and delay disease progression.
During the study, participants will receive ongoing health monitoring and assessments with our professional medical team.
Register your interest now to find out if you are eligible to participate in this study and help develop a potential new treatment approach for people living with chronic kidney disease.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.